VACCIBODY AS TO PRESENT DATA ON VB10.NEO AT UPCOMING SOCIETY FOR IMMUNOTHERAPY OF CANCER ANNUAL MEETING 2019
VACCIBODY WILL PRESENT PRELIMINARY SAFETY, EFFICACY AND IMMUNOGENICITY RESULTS FROM ITS PHASE 1/2A (DIRECT-01) STUDY OF CANCER NEOANTIGEN VACCINE VB10.NEO IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS
